Vaxart, Inc. announced the appointment of Edward B. Berg as the Company's first in-house General Counsel and Senior Vice President, effective February 14, 2022. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutical Inc., where he served as VP, Deputy General Counsel since 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9588 USD | -6.00% | +36.00% | +67.39% |
13/05 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
13/05 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.39% | 17Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-2.24% | 2.2TCr | |
-14.15% | 2.19TCr | |
-5.29% | 1.92TCr | |
-4.16% | 1.81TCr | |
-38.29% | 1.77TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- VXRT Stock
- News Vaxart, Inc.
- Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel